Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications

Open access
Garvey, W Timothy · 2022 · The Journal of Clinical Endocrinology & Metabolism

Abstract

In treating obesity as a chronic disease, the essential goal of weight loss therapy is not the quantity of weight loss as an end unto itself but rather the prevention and treatment of complications to enhance health and mitigate morbidity and mortality. This perspective on obesity care is consistent with the complications-centric American Association of Clinical Endocrinology (AACE) obesity guidelines and the diagnostic term of adiposity-based chronic disease (ABCD). Many complications require 10% to 20% weight loss to achieve therapeutic goals; however, existing obesity medications fail to produce ≥10% weight loss in the majority of patients. In June, 2021, semaglutide 2.4 mg/week was approved for chronic weight management. Phase 3 clinical trials demonstrated that this medication produced > 10% placebo-subtracted weight loss, more than half of patents lost ≥15%, and over one third lost ≥20% of baseline weight. This essentially doubles effectiveness over existing obesity medications, provides sufficient weight loss to ameliorate a broad range of complications, and qualifies as the first member of a second-generation class of obesity medications. The advent of second-generation medications fully enables a treat-to-target approach for management of ABCD as a chronic disease. Specifically, with this degree of efficacy, second-generation medications permit active management of body weight as a biomarker to targets associated with effective treatment and prevention of specific complications. ABCD can now be managed similar to other chronic diseases such as type 2 diabetes, hypertension, and atherosclerosis, which are treated to biomarker targets that can be modified based on the clinical status of individual patients [ie, hemoglobin A1c (HbA1c), blood pressure, and low-density lipoprotein cholesterol (LDL-c)] to prevent the respective complications of these diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgab848

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Treating chronic diseases to target. Abbreviations: ABCD: adiposity-based chronic disease; CHF: congestive heart failure; CKD: chronic kidney disease; CVD: cardiovascular disease; HTN: hypertension; LDL: low-density lipoprotein; MI: myocardial infarction; NAFLD: non-alcoholic fatty liver disease: NASH, non-alcoholic steatohepatitis.
Figure 1. Treating chronic diseases to target. Abbreviations: ABCD: adiposity-based chronic disease; CHF: congestive heart failure; CKD: chronic kidney disease; CVD: cardiovascular disease; HTN: hypertension; LDL: low-density lipoprotein; MI: myocardial infarction; NAFLD: non-alcoholic fatty liver disease: NASH, non-alcoholic steatohepatitis.CC BY-NC-ND · PubMed Central
Figure 2. Treating ABCD/obesity to target for prevention and treatment of complications. Abbreviations: ABCD: adiposity-based chronic disease; CVD: cardiovascular disease; HTN: hypertension; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.
Figure 2. Treating ABCD/obesity to target for prevention and treatment of complications. Abbreviations: ABCD: adiposity-based chronic disease; CVD: cardiovascular disease; HTN: hypertension; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 115

Metadata

Authors
Garvey, W. T.
Affiliations
University of Alabama at Birmingham (US)
Corresponding author
Garvey, W Timothy
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2021-12-05
Volume
107
Issue
4
Pages
e1339-e1347
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W4200495447
Cited by
110
References
58
Citations by year
2026: 16 · 2025: 37 · 2024: 31 · 2023: 16 · 2022: 10
FWCI
8.31
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes Digestive and Kidney Diseases
  • University of Alabama
  • Birmingham Diabetes Research Center (P30 DK079626)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
obesity, anti-obesity drugs, semaglutide, treat-to-target, weight loss, obesity complications, chronic disease management, obesity as chronic disease
MeSH terms
Chronic Disease, Diabetes Mellitus, Type 2, Endocrinology, Humans, Obesity, Weight Loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. https://app.cochat.ai/papers/10.1210/clinem/dgab848
The paper
Garvey, W. T. (2022). New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgab848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.